Overview

Join us for an exclusive evening of elevated dining and strategic networking, highlighted by an expert-led panel discussion on the latest political and regulatory developments shaping the future of the biotech and pharmaceutical industries.

Panel Topics:

• FDA policies under the new Trump administration
• Implications of the Loper Bright case and changes to the Chevron doctrine
• Best practices for obtaining early FDA feedback and streamlining approvals
• Insights into the federal funding landscape in 2025
• Strategies to navigate new government opportunities and avoid regulatory pitfalls